This unmet clinical need has prompted us to investigate whether PBC-specific ANA (i.e., anti-gp210 and anti-sp100 antibodies) may provide meaningful diagnostic and prognostic data. This evidence concerns the gene BTG3 and primary biliary cholangitis.